Circassia Pharmaceuticals Dividends - CIR

Circassia Pharmaceuticals Dividends - CIR

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Circassia Pharmaceuticals Plc CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  0.10 0.4% 25.20 25.30 25.00 25.30 25.10 08:38:29
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Circassia Pharmaceuticals CIR Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
01/01/1970FinalGBP031/12/200431/12/200501/01/197001/01/197001/01/19700
01/01/1970FinalGBP031/12/200331/12/200401/01/197001/01/197001/01/19700
01/01/1970FinalGBP031/12/200231/12/200301/01/197001/01/197001/01/19700

Top Dividend Posts

DateSubject
19/12/2019
14:43
the abbot: Here's Ian Johnsons Golden handshake. hTTps://investegate.co.uk/circassia-pharma-plc--cir-/rns/grant-of-options/201912191403425322X/ Grant of options Oxford, UK - 19 December 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has granted nil-cost options ("Options") today over 4,322,767 ordinary shares in the Company ("Ordinary Shares") to Ian Johnson, who was appointed as Executive Chairman of the Company on 5 December 2019, under the 2019 Performance Share Plan. The Options have been granted at nil-cost and will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the share price reaching 62.4p, equating to three times the average closing price for an Ordinary Share for the 10 dealing days immediately preceding the grant date, for at least 30 consecutive dealing days or a liquidity event occurring above this level. Should some or all of the Options be exercised, the Ordinary Shares will be purchased on the open market by The Circassia Pharmaceuticals plc Employee Benefit Trust on behalf of Mr Johnson.
19/12/2019
14:43
the abbot: hTTps://investegate.co.uk/circassia-pharma-plc--cir-/rns/grant-of-options/201912191403425322X/ Grant of options Oxford, UK - 19 December 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has granted nil-cost options ("Options") today over 4,322,767 ordinary shares in the Company ("Ordinary Shares") to Ian Johnson, who was appointed as Executive Chairman of the Company on 5 December 2019, under the 2019 Performance Share Plan. The Options have been granted at nil-cost and will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the share price reaching 62.4p, equating to three times the average closing price for an Ordinary Share for the 10 dealing days immediately preceding the grant date, for at least 30 consecutive dealing days or a liquidity event occurring above this level. Should some or all of the Options be exercised, the Ordinary Shares will be purchased on the open market by The Circassia Pharmaceuticals plc Employee Benefit Trust on behalf of Mr Johnson.
19/12/2019
09:53
the abbot: Seems to me that there were some good negotiation conducted and associated with this product, thus if beyondair want out then they must feel the deal conducted with AIT Therapeutics seriously undervalued the product, thus they are squirming. Bearing in mind the product is not even launched and only the initial and pre submission FDA stage payment has been made, (In shares) I would find it hard to see how something has already been breached. Under the terms of the companies' agreement, AIT grants Circassia an exclusive license for the commercialisation of AIT's nitric oxide generator and delivery system for use at concentrations of = 80 ppm in the hospital setting in the United States and China. AIT will receive contingent payments based upon the achievement of certain milestones, which Circassia currently anticipates satisfying through the issuance of new Ordinary Shares in the Company, at a discount of 5% to a volume weighted average share price. · $7.35 million payable immediately · $3.15 million payable upon successful completion of a pre-submission meeting with FDA The above have been settled. · $12.6 million payable upon the sooner of the product's US launch in PPHN or 90 days post FDA approval · $8.4 million payable upon label expansion in a related indication in the US · $1.05 million payable on launch in China. In addition, AIT will receive royalties from Circassia based upon gross profits on future sales of the product: · 5% on the first $50 million in cumulative gross profit in the US · 5% on the first $20 million in cumulative gross profit in China; and thereafter: · 15% on annual gross profit of up to and including $100 million (US and China combined) · 20% on annual gross profit in excess of $100 million (US and China combined). ------------- IMO they are trying to squirm out of the contract on grounds of company reorganisation due to the recent Board changes. That will not wash. IMO Circassia made a great deal with AIT and now BeyondAir have some cash and want to get out of the deal. Interesting is that 6 days ago, Beyond Air, Inc. Announced Closing of $11.5 Million Public Offering and Private Placement of Common Stock and Exercise of Option to Purchase Additional Shares. They stated "Company intends to use the net proceeds from the public offering and the concurrent private placement for working capital and general corporate purposes, which may include clinical studies required to gain regulatory approvals, including new indications for LungFit™, implementation of adequate systems and controls to allow for regulatory approvals, further development of the LungFit™ for use in the home, investing in or acquiring companies that are synergistic with or complementary to the Company’s technologies, and licensing activities related to the Company’s current and future product candidates." Seems to me they want to improve the product further and don't want Circassia getting a free ride
19/12/2019
08:40
the abbot: Seems to me that there were some good negotiation conducted and associated with this product, thus if beyondair want out then they must feel the deal conducted with AIT Therapeutics seriously undervalued the product, thus they are squirming. Bearing in mind the product is not even launched and only the initial and pre submission FDA stage payment has been made, I would find it hard to see how something has already been breached. Under the terms of the companies' agreement, AIT grants Circassia an exclusive license for the commercialisation of AIT's nitric oxide generator and delivery system for use at concentrations of ≤ 80 ppm in the hospital setting in the United States and China. AIT will receive contingent payments based upon the achievement of certain milestones, which Circassia currently anticipates satisfying through the issuance of new Ordinary Shares in the Company, at a discount of 5% to a volume weighted average share price. · $7.35 million payable immediately · $3.15 million payable upon successful completion of a pre-submission meeting with FDA · $12.6 million payable upon the sooner of the product's US launch in PPHN or 90 days post FDA approval · $8.4 million payable upon label expansion in a related indication in the US · $1.05 million payable on launch in China. In addition, AIT will receive royalties from Circassia based upon gross profits on future sales of the product: · 5% on the first $50 million in cumulative gross profit in the US · 5% on the first $20 million in cumulative gross profit in China; and thereafter: · 15% on annual gross profit of up to and including $100 million (US and China combined) · 20% on annual gross profit in excess of $100 million (US and China combined).
19/12/2019
08:02
74tom: Yep happy with this thread thank you. Regarding the RNS, it drew my attention to the fact that Beyond Air received 12.3m Circassia shares in Jan 2019 (equal to 3.3% of the 369m shares in issue at the time), and I can’t find a holdings RNS for them? Is this because they are sub 5% and an international holder? Another 5m shares issued in Feb too. So Circassia paid £0 cash consideration for the rights which is one positive... From the Beyond Air SEC filings, it shows they held $5.6m of Circassia shares at 31st March, at 30th September they only held $1.89m ($1.89m / $0.2 per share = 9.45m shares) so they had sold around 6m shares between issue and end of September. Another depressant on the share price. Detail on page 16 of the below; hxxps://www.beyondair.net/investors/sec-filings/quarterly-reports/content/0001493152-19-016559/0001493152-19-016559.pdf The cynic in me things they have now sold down all their shares and are looking for a way to wrest back control of their asset in two key markets - interesting to see what unfolds!
08/12/2019
14:27
74tom: Article 5: https://www.investorschronicle.co.uk/shares/2019/05/01/circassia-slashes-net-cash-outflow/ Drug developers require a steady stream of positive clinical updates to underpin market valuations. Circassia Pharmaceuticals (CIR) provided shareholders with precisely that a month ahead of these full-year figures when it revealed that US regulators had given the green light to two of its chronic obstructive pulmonary disease (COPD) treatments. It is too early to say whether the news has arrested the share price decline of the previous 12-months, but given that very few UK-sponsored drugs have been approved in the US in the past few years, so the news - particularly in relation to the Duaklir drug - would not have gone unnoticed amongst the sector heavyweights. The drugs are complementary in that patients using its existing COPD treatment Tudorza (which got the go-ahead for the inclusion of new clinical data on its label) can move on to Duaklir if their condition deteriorates without needing to change their inhaler device. Bloomberg consensus gives revenues of £64.5m for the December 2019 year-end, with an accompanying adjusted earnings loss of 7.6p a share, before £84.8m and a 5.2p loss in the following year. IC View Duaklir was initially approved in the European Union five years ago, but the US launch in the second half of 2019 is highly significant given the potential up-scale. With a new revenue stream in prospect, 2018 may come to be seen as a watershed for the company. Though the net cash-outflow fell by two-thirds to £18.8m, the continued backing by AstraZeneca (AZN) – which boosted its holding to 19.9 per cent midway through last year – has been crucial. However, given the lowly free-float, shareholders may struggle to buy into the US growth story. Hold. Last IC view: Hold, 34p, 01 Apr 2019”
08/12/2019
14:21
74tom: Article 3: https://www.investorschronicle.co.uk/tips-ideas/2018/09/28/circassia-is-heading-for-aim/ Circassia’s (CIR) chief executive, Steve Harris, is rightly proud of his business's transition. Instead of “packing up and going home” after the failure of its allergy trial in 2016, the group has become a respiratory pharma specialist with a strong commercial presence in the US and plans to expand into China. That doesn’t mean the last few years haven’t been tough for shareholders and these half-year results reveal continued disturbances as the dust settles. AstraZeneca’s (AZN) decision to up its stake to 19.9 per cent (thus reducing Circassia’s cash contribution to the partnership) has lowered the free float below the London Stock Exchange’s threshold, meaning Circassia is having to move to Aim. But the rewards from the new strategy are beginning to emerge. Adjusted losses from continuing operations fell more than 50 per cent to £13.4m in the first half, due to a sharp drop in research and development expenditure. Management has halted investment in the new drugs pipeline in favour of Duaklir and Tudorza – the two medicines from the Astra partnership, both of which will receive US regulatory updates in March 2019. Sales from Tudorza rose 4 per cent compared with the second half of 2017 thanks to improved marketing efforts, while Duaklir has the potential to generate peak sales of $180m, according to analysts. IC View Progress from the Astra partnership has the potential to catalyse share price recovery after a difficult few years for Circassia investors. This is certainly an investment that requires patience, but the forecast sales growth from Duaklir and Tudorza in the US and the commercial opportunity in China keep us positive. Buy. Last IC View: Buy, 77p, 13 Aug 2018”
08/12/2019
14:19
74tom: Article 2: https://www.investorschronicle.co.uk/tips-ideas/2018/08/13/circassia-s-drug-filing-accepted-by-fda/ Since gaining access to two of AstraZeneca’s (AZN) respiratory drugs in March 2017, Circassia (CIR) has delivered plenty of good news – positive clinical updates from the Astra medicines, steady commercial expansion and a sharp drop in research and development spending. And yet the share price has fallen more than a fifth since then. Most recently, the respiratory specialist – which has realigned its strategy since its major allergy trial failure in 2016 – has had its regulatory submission for Duaklir and Tudorza (the two drugs from Astra) accepted by the US Food and Drug Administration. That means it is likely to gain approval in March next year, which should boost group revenue. Broker Stifel thinks Duaklir has the potential to generate annual revenue of over $200m (£157m). As Circassia creeps closer to a sharp uptick in commercial revenues from the Astra deal, we see no reason for recent share price weakness and retain our buy recommendation at 77p. Last IC View: Buy, 91p 24 Apr 2018“ Shares in issue: 357m, market cap: £274m
08/12/2019
14:16
74tom: Article 1; https://www.investorschronicle.co.uk/tips-ideas/2018/04/24/novel-respiratory-drugs-give-circassia-commercial-edge/ “Tip update: Buy at 91p The identity crisis at Circassia (CIR) stepped up a notch in 2017. As well as walking away from its allergy drugs business (which suffered after a major trial failure in 2016), the group is tapering investment in its generic respiratory portfolio following product development delays. Pure commercial pharma is the new focus, which is why the sales and marketing team now makes up three-quarters of the group’s headcount, while research and development (R&D) staff have been cut by 40 per cent. Key to the group’s new strategy is its joint venture with AstraZeneca, which has given it access to the US commercial rights to two respiratory drugs, and its asthma drug NIOX, which recorded a 26 per cent increase in worldwide sales. Growth from these drugs is expected to push group revenue up to £80m by 2019. Meanwhile, the operational realignment is expected to slash R&D costs, which will help lower adjusted cash losses to £27.6m in 2018 and £7.7m the year after that, according to broker Numis (from £34.7m in 2017). Excluding the discontinued programmes, a £37m impairment on product delays and the £42m one-off expenditure on the joint venture, R&D fell 54 per cent to £20.9m in 2017. What’s more, management is planning on paying for the next phase of drug development in the joint venture with new shares issued to AstraZeneca, helping to preserve cash. IC View Although still lossmaking, we feel Circassia continues to be unduly punished for its allergy disappointment and think pharmaceutical and commercial catalysts should push the share price higher in the coming months. Buy.“ Shares in issue at 24/04/18 : 333m, market cap £303m
01/5/2019
17:42
gersemi: 6 hours ago Circassia slashes net cash outflow By Mark Robinson Drug developers require a steady stream of positive clinical updates to underpin market valuations. Circassia Pharmaceuticals (CIE) provided shareholders with precisely that a month ahead of these full-year figures when it revealed that US regulators had given the green light for two of its chronic obstructive pulmonary disease (COPD) treatments. It is too early to say whether the news has arrested the share price decline of the previous 12-months, but given that very few UK-sponsored drugs have been approved in the US in the past few years, so the news - particularly in relation to the Duaklir drug - would not have gone unnoticed amongst the sector heavyweights. The drugs are complementary in that patients using its existing COPD treatment Tudorza (which got the go-ahead for the inclusion of new clinical data on its label) can move on to Duaklir if their condition deteriorates without needing to change their inhaler device. Bloomberg consensus gives revenues of £64.5m for the December 2019 year-end, with an accompanying adjusted earnings loss of 7.6p a share, before £84.8m and a 5.2p loss in the following year. CIRCASSIA PHARMACEUTICALS (CIR) ORD PRICE: 32p MARKET VALUE: £ 120m TOUCH: 31.2-32p 12-MONTH HIGH: 98p LOW: 25p DIVIDEND YIELD: NIL PE RATIO: NA NET ASSET VALUE: 34p* NET CASH: £40.7m Year to 31 Dec Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 nil -44.0 -21 nil 2015 10.8 -62.8 -20 nil 2016 23.1 -38.8 -48 nil 2017 (restated) 46.3 -74.2 -19 nil 2018 48.3 -55.8 -14 nil % change +4 - - - Ex-div: - Payment: - *Includes intangible assets of £231m, or 61.5p a share. IC View Duaklir was initially approved in the European Union five years ago, but the US launch in the second half of 2019 is highly significant given the potential up-scale. With a new revenue stream in prospect, 2018 may come to be seen as a watershed for the company. Though the net cash-outflow fell by two-thirds to £18.8m, the continued backing by AstraZeneca (AZN), which boosted its holding to 19.9 per cent midway through last year, has been crucial. However, given the lowly free-float, shareholders may struggle to buy into the US growth story. Hold. Last IC view: Hold, 34p, 01 Apr 2019 end
Your Recent History
LSE
CIR
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200120 09:01:08